Prostate adenocarcinoma
Drug research and approvals for prostate adenocarcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 182 studies of prostate adenocarcinoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.
- Recruiting worldwide: 182
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 182 recruiting on ClinicalTrials.gov ↗- Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate…NCT07466498 · Phase 2 · Fred Hutchinson Cancer Center · starts Dec 1, 2026
- Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803…NCT07574541 · Phase 2 · National Cancer Institute (NCI) · starts Nov 19, 2026
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and…NCT07667400 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts Nov 19, 2026
- Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment…NCT07698535 · Phase 2 · University of Washington · starts Nov 15, 2026
- Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno)NCT06960798 · Not reported · University of Oklahoma · starts Nov 2, 2026
- RYZ711 Diagnostic Platform StudyNCT07862582 · Phase 1 / Phase 2 · RayzeBio, Inc. · starts Oct 5, 2026
- Study of Oral MRT-2359 With Apalutamide in Prostate CancerNCT07745361 · Phase 2 · Monte Rosa Therapeutics, Inc · starts Aug 18, 2026
- SL-28 for Advanced Solid TumoursNCT07341737 · Phase 1 / Phase 2 · Second Life Therapeutics · starts Aug 14, 2026
- Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialNCT07650240 · Phase 2 · Mayo Clinic · starts Aug 4, 2026
- Development of an Intraoperative Adaptive Biopsy System for Prostate Cancer: Integrating Imaging Navigation With…NCT07856017 · Not reported · Shanghai Zhongshan Hospital · starts Jul 21, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Mar 26, 2024 | Phase III study of hypofractionated, dose escalation radiotherapy and brachytherapy for intermediate risk adenocarcinoma of the prostate with 6 versus 12…LEUPROLIDE | HOPITAL CHARLES LEMOYNE | Pending |
| Feb 28, 2022 | A phase III double-blind, randomised, placebo-controlled study assessing the efficacy and safety of capivasertib + docetaxel versus placebo + docetaxel as…CAPIVASERTIB (AZD5363)/ DOCETAXEL | AstraZeneca Pharmaceuticals LP | Closed |
| May 16, 2018 | Prevention of metabolic syndrome and increased weight using metformin concurrent to androgen deprivation therapy and radiotherapy for locally advanced…METFORMIN | PRAIRIE MOUNTAIN HEALTH | Ongoing |
| Jun 17, 2015 | Barrier-p trial: biomarkers of androgen response and resistance in evolution during a rising psaATORVASTATIN/ METFORMIN | UNIVERSITY HEALTH NETWORK | Ongoing |
| Oct 23, 2014 | Phase III study of hypofractionated, dose escalation radiotherapy vs. standard pelvic radiation therapy followed by hdr brachy boost for high risk…LEUPROLIDE/ BICALUTAMIDE | JEWISH GENERAL HOSPITAL | Ongoing |
| Jul 2, 2014 | Premium - prevention of metabolic syndrome and increased weight using metformin concurrent to androgen deprivation therapy and radiotherapy for high risk,…METFORMIN | ALBERTA HEALTH SERVICES | Closed |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA